Review



mic 0 86 e coli atcc 25922 gar 936 auc 0 80 e coli atcc 25922 gar 936 time  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC mic 0 86 e coli atcc 25922 gar 936 auc 0 80 e coli atcc 25922 gar 936 time
    Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline
    Mic 0 86 E Coli Atcc 25922 Gar 936 Auc 0 80 E Coli Atcc 25922 Gar 936 Time, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 54469 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mic 0 86 e coli atcc 25922 gar 936 auc 0 80 e coli atcc 25922 gar 936 time/product/ATCC
    Average 99 stars, based on 54469 article reviews
    mic 0 86 e coli atcc 25922 gar 936 auc 0 80 e coli atcc 25922 gar 936 time - by Bioz Stars, 2026-03
    99/100 stars

    Images

    1) Product Images from "In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria"

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    Journal:

    doi:

    Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline
    Figure Legend Snippet: Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline

    Techniques Used: In Vitro

    Dose-effect relationship of the glycylcyclines against various organisms, using a twice-daily dosing regimen
    Figure Legend Snippet: Dose-effect relationship of the glycylcyclines against various organisms, using a twice-daily dosing regimen

    Techniques Used:

    In vivo PAE of GAR-936 after administration of 3 mg/kg subcutaneously to neutropenic mice infected with S. pneumoniae ATCC 10813 (a) and E. coli ATCC 25922 (b). t>MIC, period when an active concentration of GAR-936 is present; ●, untreated mice; ○, GAR-936-treated mice.
    Figure Legend Snippet: In vivo PAE of GAR-936 after administration of 3 mg/kg subcutaneously to neutropenic mice infected with S. pneumoniae ATCC 10813 (a) and E. coli ATCC 25922 (b). t>MIC, period when an active concentration of GAR-936 is present; ●, untreated mice; ○, GAR-936-treated mice.

    Techniques Used: In Vivo, Infection, Concentration Assay

    Nonlinear regression analysis of the results of the experimental thigh muscle infection on predictors of drug efficacy a
    Figure Legend Snippet: Nonlinear regression analysis of the results of the experimental thigh muscle infection on predictors of drug efficacy a

    Techniques Used: Infection



    Similar Products

    mic 0 86 e coli atcc 25922 gar 936 auc 0 80 e coli atcc 25922 gar 936 time  (ATCC)
    99
    ATCC mic 0 86 e coli atcc 25922 gar 936 auc 0 80 e coli atcc 25922 gar 936 time
    Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline
    Mic 0 86 E Coli Atcc 25922 Gar 936 Auc 0 80 E Coli Atcc 25922 Gar 936 Time, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mic 0 86 e coli atcc 25922 gar 936 auc 0 80 e coli atcc 25922 gar 936 time/product/ATCC
    Average 99 stars, based on 1 article reviews
    mic 0 86 e coli atcc 25922 gar 936 auc 0 80 e coli atcc 25922 gar 936 time - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    e coli atcc 25922 gar  (ATCC)
    99
    ATCC e coli atcc 25922 gar
    Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline
    E Coli Atcc 25922 Gar, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e coli atcc 25922 gar/product/ATCC
    Average 99 stars, based on 1 article reviews
    e coli atcc 25922 gar - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline

    Article Snippet: The only exception to this observation was the combination of GAR-936 and S. pneumoniae 1199, for which both AUC and time above the MIC were important in predicting outcome ( R 2 = 0.83 and 0.82, respectively). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4 caption a7 Relationship between pharmacokinetic-pharmacodynamic parameters and therapeutic efficacy of GAR-936 (free drug) against S. pneumoniae 1199 in the neutropenic mouse thigh muscle infection model ( R 2 = 0.82, 0.83, and 0.54 for panels a, b, and c, respectively). (a) time above the 0.5 × MIC versus effect. (b) Log AUC versus effect. (c) Log C max versus effect. table ft1 table-wrap mode="anchored" t5 TABLE 4 caption a7 Microorganism Drug Parameter R 2 S. pneumoniae 1199 GAR-936 AUC 0.83 S. pneumoniae 1199 GAR-936 Time above MIC 0.82 S. pneumoniae 1199 WAY 152,288 AUC 0.77 S. pneumoniae 1199 WAY 152,288 Time above 0.5× the MIC 0.86 E. coli ATCC 25922 GAR-936 AUC 0.80 E. coli ATCC 25922 GAR-936 Time above 0.5× the MIC 0.93 E. coli ATCC 25922 WAY 152,288 AUC 0.56 E. coli ATCC 25922 WAY 152,288 Time above 4× the MIC 0.91 K. pneumoniae ATCC 43816 GAR-936 AUC 0.73 K. pneumoniae ATCC 43816 GAR-936 Time above MIC 0.76 K. pneumoniae ATCC 43816 WAY 152,288 AUC 0.83 K. pneumoniae ATCC 43816 WAY 152,288 Time above MIC 0.84 Open in a separate window a The predictors of drug efficacy were time that levels exceeded a certain fraction of the MIC and AUC.

    Techniques: In Vitro

    Dose-effect relationship of the glycylcyclines against various organisms, using a twice-daily dosing regimen

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Dose-effect relationship of the glycylcyclines against various organisms, using a twice-daily dosing regimen

    Article Snippet: The only exception to this observation was the combination of GAR-936 and S. pneumoniae 1199, for which both AUC and time above the MIC were important in predicting outcome ( R 2 = 0.83 and 0.82, respectively). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4 caption a7 Relationship between pharmacokinetic-pharmacodynamic parameters and therapeutic efficacy of GAR-936 (free drug) against S. pneumoniae 1199 in the neutropenic mouse thigh muscle infection model ( R 2 = 0.82, 0.83, and 0.54 for panels a, b, and c, respectively). (a) time above the 0.5 × MIC versus effect. (b) Log AUC versus effect. (c) Log C max versus effect. table ft1 table-wrap mode="anchored" t5 TABLE 4 caption a7 Microorganism Drug Parameter R 2 S. pneumoniae 1199 GAR-936 AUC 0.83 S. pneumoniae 1199 GAR-936 Time above MIC 0.82 S. pneumoniae 1199 WAY 152,288 AUC 0.77 S. pneumoniae 1199 WAY 152,288 Time above 0.5× the MIC 0.86 E. coli ATCC 25922 GAR-936 AUC 0.80 E. coli ATCC 25922 GAR-936 Time above 0.5× the MIC 0.93 E. coli ATCC 25922 WAY 152,288 AUC 0.56 E. coli ATCC 25922 WAY 152,288 Time above 4× the MIC 0.91 K. pneumoniae ATCC 43816 GAR-936 AUC 0.73 K. pneumoniae ATCC 43816 GAR-936 Time above MIC 0.76 K. pneumoniae ATCC 43816 WAY 152,288 AUC 0.83 K. pneumoniae ATCC 43816 WAY 152,288 Time above MIC 0.84 Open in a separate window a The predictors of drug efficacy were time that levels exceeded a certain fraction of the MIC and AUC.

    Techniques:

    In vivo PAE of GAR-936 after administration of 3 mg/kg subcutaneously to neutropenic mice infected with S. pneumoniae ATCC 10813 (a) and E. coli ATCC 25922 (b). t>MIC, period when an active concentration of GAR-936 is present; ●, untreated mice; ○, GAR-936-treated mice.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: In vivo PAE of GAR-936 after administration of 3 mg/kg subcutaneously to neutropenic mice infected with S. pneumoniae ATCC 10813 (a) and E. coli ATCC 25922 (b). t>MIC, period when an active concentration of GAR-936 is present; ●, untreated mice; ○, GAR-936-treated mice.

    Article Snippet: The only exception to this observation was the combination of GAR-936 and S. pneumoniae 1199, for which both AUC and time above the MIC were important in predicting outcome ( R 2 = 0.83 and 0.82, respectively). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4 caption a7 Relationship between pharmacokinetic-pharmacodynamic parameters and therapeutic efficacy of GAR-936 (free drug) against S. pneumoniae 1199 in the neutropenic mouse thigh muscle infection model ( R 2 = 0.82, 0.83, and 0.54 for panels a, b, and c, respectively). (a) time above the 0.5 × MIC versus effect. (b) Log AUC versus effect. (c) Log C max versus effect. table ft1 table-wrap mode="anchored" t5 TABLE 4 caption a7 Microorganism Drug Parameter R 2 S. pneumoniae 1199 GAR-936 AUC 0.83 S. pneumoniae 1199 GAR-936 Time above MIC 0.82 S. pneumoniae 1199 WAY 152,288 AUC 0.77 S. pneumoniae 1199 WAY 152,288 Time above 0.5× the MIC 0.86 E. coli ATCC 25922 GAR-936 AUC 0.80 E. coli ATCC 25922 GAR-936 Time above 0.5× the MIC 0.93 E. coli ATCC 25922 WAY 152,288 AUC 0.56 E. coli ATCC 25922 WAY 152,288 Time above 4× the MIC 0.91 K. pneumoniae ATCC 43816 GAR-936 AUC 0.73 K. pneumoniae ATCC 43816 GAR-936 Time above MIC 0.76 K. pneumoniae ATCC 43816 WAY 152,288 AUC 0.83 K. pneumoniae ATCC 43816 WAY 152,288 Time above MIC 0.84 Open in a separate window a The predictors of drug efficacy were time that levels exceeded a certain fraction of the MIC and AUC.

    Techniques: In Vivo, Infection, Concentration Assay

    Nonlinear regression analysis of the results of the experimental thigh muscle infection on predictors of drug efficacy a

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Nonlinear regression analysis of the results of the experimental thigh muscle infection on predictors of drug efficacy a

    Article Snippet: The only exception to this observation was the combination of GAR-936 and S. pneumoniae 1199, for which both AUC and time above the MIC were important in predicting outcome ( R 2 = 0.83 and 0.82, respectively). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 4 caption a7 Relationship between pharmacokinetic-pharmacodynamic parameters and therapeutic efficacy of GAR-936 (free drug) against S. pneumoniae 1199 in the neutropenic mouse thigh muscle infection model ( R 2 = 0.82, 0.83, and 0.54 for panels a, b, and c, respectively). (a) time above the 0.5 × MIC versus effect. (b) Log AUC versus effect. (c) Log C max versus effect. table ft1 table-wrap mode="anchored" t5 TABLE 4 caption a7 Microorganism Drug Parameter R 2 S. pneumoniae 1199 GAR-936 AUC 0.83 S. pneumoniae 1199 GAR-936 Time above MIC 0.82 S. pneumoniae 1199 WAY 152,288 AUC 0.77 S. pneumoniae 1199 WAY 152,288 Time above 0.5× the MIC 0.86 E. coli ATCC 25922 GAR-936 AUC 0.80 E. coli ATCC 25922 GAR-936 Time above 0.5× the MIC 0.93 E. coli ATCC 25922 WAY 152,288 AUC 0.56 E. coli ATCC 25922 WAY 152,288 Time above 4× the MIC 0.91 K. pneumoniae ATCC 43816 GAR-936 AUC 0.73 K. pneumoniae ATCC 43816 GAR-936 Time above MIC 0.76 K. pneumoniae ATCC 43816 WAY 152,288 AUC 0.83 K. pneumoniae ATCC 43816 WAY 152,288 Time above MIC 0.84 Open in a separate window a The predictors of drug efficacy were time that levels exceeded a certain fraction of the MIC and AUC.

    Techniques: Infection

    Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Organisms used and in vitro susceptibilities to GAR-936, WAY 152,288, and minocycline

    Article Snippet: The sigmoid curve represents the dose-effect curve established according to the Hill equation. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Drug E max a ED 50 (mg/kg/day) BD (mg/kg/day) S. pneumoniae ATCC 10813 GAR-936 7.3 1.6 1.4 WAY 152,288 7.3 1.9 1.6 ATCC 49619 GAR-936 5.0 1.7 2.0 WAY 152,288 5.0 1.4 1.7 1199 GAR-936 6.6 1.1 0.8 WAY 152,288 6.6 1.0 0.7 1020 GAR-936 5.3 2.3 2.6 WAY 152,288 5.3 2.2 2.4 1293 GAR-936 6.8 3.5 3.0 WAY 152,288 6.8 2.9 2.5 1396 GAR-936 6.2 9.6 5.9 WAY 152,288 6.2 3.1 2.8 S. aureus ATCC 25923 GAR-936 3.1 4.0 7.2 WAY 152,288 3.5 4.0 4.3 ATCC 33591 GAR-936 4.9 33 23 WAY 152,288 5.6 39 23 ATCC 29213 GAR-936 3.9 25 19 WAY 152,288 4.4 22 12 WIS-2 GAR-936 3.6 41 23 WAY 152,288 3.2 26 16 E. coli ATCC 25922 GAR-936 5.5 11 11 WAY 152,288 5.5 11 6.2 894 GAR-936 5.3 5.8 7.5 WAY 152,288 5.3 12 14 K. pneumoniae ATCC 43816 GAR-936 4.4 115 151 WAY 152,288 4.4 48 82 Open in a separate window a E max is expressed as the log 10 difference in numbers between control animals and treated animals.

    Techniques: In Vitro

    Effects of various GAR-936 (a), WAY 152,288 (b), and minocycline (c) dosage regimens on the number of S. pneumoniae ATCC 10813 organisms in the neutropenic mouse thigh muscle infection model after 48 h of treatment. The dashed horizontal line represents the number of CFU per thigh at the start of treatment. ●, single dose; ○, once-daily dose; ▾, twice-daily dose; ▿, four-times-daily dose; ——, single dose; ······, once-daily dose; –––, twice-daily dose; —··, four-times-daily dose; —–, log CFU at start of treatment.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Effects of various GAR-936 (a), WAY 152,288 (b), and minocycline (c) dosage regimens on the number of S. pneumoniae ATCC 10813 organisms in the neutropenic mouse thigh muscle infection model after 48 h of treatment. The dashed horizontal line represents the number of CFU per thigh at the start of treatment. ●, single dose; ○, once-daily dose; ▾, twice-daily dose; ▿, four-times-daily dose; ——, single dose; ······, once-daily dose; –––, twice-daily dose; —··, four-times-daily dose; —–, log CFU at start of treatment.

    Article Snippet: The sigmoid curve represents the dose-effect curve established according to the Hill equation. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Drug E max a ED 50 (mg/kg/day) BD (mg/kg/day) S. pneumoniae ATCC 10813 GAR-936 7.3 1.6 1.4 WAY 152,288 7.3 1.9 1.6 ATCC 49619 GAR-936 5.0 1.7 2.0 WAY 152,288 5.0 1.4 1.7 1199 GAR-936 6.6 1.1 0.8 WAY 152,288 6.6 1.0 0.7 1020 GAR-936 5.3 2.3 2.6 WAY 152,288 5.3 2.2 2.4 1293 GAR-936 6.8 3.5 3.0 WAY 152,288 6.8 2.9 2.5 1396 GAR-936 6.2 9.6 5.9 WAY 152,288 6.2 3.1 2.8 S. aureus ATCC 25923 GAR-936 3.1 4.0 7.2 WAY 152,288 3.5 4.0 4.3 ATCC 33591 GAR-936 4.9 33 23 WAY 152,288 5.6 39 23 ATCC 29213 GAR-936 3.9 25 19 WAY 152,288 4.4 22 12 WIS-2 GAR-936 3.6 41 23 WAY 152,288 3.2 26 16 E. coli ATCC 25922 GAR-936 5.5 11 11 WAY 152,288 5.5 11 6.2 894 GAR-936 5.3 5.8 7.5 WAY 152,288 5.3 12 14 K. pneumoniae ATCC 43816 GAR-936 4.4 115 151 WAY 152,288 4.4 48 82 Open in a separate window a E max is expressed as the log 10 difference in numbers between control animals and treated animals.

    Techniques: Infection

    Dose-effect relationship of the glycylcyclines GAR-936 (a) and WAY 152,288 (b) in an experimental thigh muscle infection with S. pneumoniae 1199 in neutropenic mice. Each point represents the results for a single mouse. The sigmoid curve represents the dose-effect curve established according to the Hill equation.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Dose-effect relationship of the glycylcyclines GAR-936 (a) and WAY 152,288 (b) in an experimental thigh muscle infection with S. pneumoniae 1199 in neutropenic mice. Each point represents the results for a single mouse. The sigmoid curve represents the dose-effect curve established according to the Hill equation.

    Article Snippet: The sigmoid curve represents the dose-effect curve established according to the Hill equation. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Drug E max a ED 50 (mg/kg/day) BD (mg/kg/day) S. pneumoniae ATCC 10813 GAR-936 7.3 1.6 1.4 WAY 152,288 7.3 1.9 1.6 ATCC 49619 GAR-936 5.0 1.7 2.0 WAY 152,288 5.0 1.4 1.7 1199 GAR-936 6.6 1.1 0.8 WAY 152,288 6.6 1.0 0.7 1020 GAR-936 5.3 2.3 2.6 WAY 152,288 5.3 2.2 2.4 1293 GAR-936 6.8 3.5 3.0 WAY 152,288 6.8 2.9 2.5 1396 GAR-936 6.2 9.6 5.9 WAY 152,288 6.2 3.1 2.8 S. aureus ATCC 25923 GAR-936 3.1 4.0 7.2 WAY 152,288 3.5 4.0 4.3 ATCC 33591 GAR-936 4.9 33 23 WAY 152,288 5.6 39 23 ATCC 29213 GAR-936 3.9 25 19 WAY 152,288 4.4 22 12 WIS-2 GAR-936 3.6 41 23 WAY 152,288 3.2 26 16 E. coli ATCC 25922 GAR-936 5.5 11 11 WAY 152,288 5.5 11 6.2 894 GAR-936 5.3 5.8 7.5 WAY 152,288 5.3 12 14 K. pneumoniae ATCC 43816 GAR-936 4.4 115 151 WAY 152,288 4.4 48 82 Open in a separate window a E max is expressed as the log 10 difference in numbers between control animals and treated animals.

    Techniques: Infection

    Dose-effect relationship of the glycylcyclines against various organisms, using a twice-daily dosing regimen

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Dose-effect relationship of the glycylcyclines against various organisms, using a twice-daily dosing regimen

    Article Snippet: The sigmoid curve represents the dose-effect curve established according to the Hill equation. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Drug E max a ED 50 (mg/kg/day) BD (mg/kg/day) S. pneumoniae ATCC 10813 GAR-936 7.3 1.6 1.4 WAY 152,288 7.3 1.9 1.6 ATCC 49619 GAR-936 5.0 1.7 2.0 WAY 152,288 5.0 1.4 1.7 1199 GAR-936 6.6 1.1 0.8 WAY 152,288 6.6 1.0 0.7 1020 GAR-936 5.3 2.3 2.6 WAY 152,288 5.3 2.2 2.4 1293 GAR-936 6.8 3.5 3.0 WAY 152,288 6.8 2.9 2.5 1396 GAR-936 6.2 9.6 5.9 WAY 152,288 6.2 3.1 2.8 S. aureus ATCC 25923 GAR-936 3.1 4.0 7.2 WAY 152,288 3.5 4.0 4.3 ATCC 33591 GAR-936 4.9 33 23 WAY 152,288 5.6 39 23 ATCC 29213 GAR-936 3.9 25 19 WAY 152,288 4.4 22 12 WIS-2 GAR-936 3.6 41 23 WAY 152,288 3.2 26 16 E. coli ATCC 25922 GAR-936 5.5 11 11 WAY 152,288 5.5 11 6.2 894 GAR-936 5.3 5.8 7.5 WAY 152,288 5.3 12 14 K. pneumoniae ATCC 43816 GAR-936 4.4 115 151 WAY 152,288 4.4 48 82 Open in a separate window a E max is expressed as the log 10 difference in numbers between control animals and treated animals.

    Techniques:

    In vivo PAE of GAR-936 after administration of 3 mg/kg subcutaneously to neutropenic mice infected with S. pneumoniae ATCC 10813 (a) and E. coli ATCC 25922 (b). t>MIC, period when an active concentration of GAR-936 is present; ●, untreated mice; ○, GAR-936-treated mice.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: In vivo PAE of GAR-936 after administration of 3 mg/kg subcutaneously to neutropenic mice infected with S. pneumoniae ATCC 10813 (a) and E. coli ATCC 25922 (b). t>MIC, period when an active concentration of GAR-936 is present; ●, untreated mice; ○, GAR-936-treated mice.

    Article Snippet: The sigmoid curve represents the dose-effect curve established according to the Hill equation. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Drug E max a ED 50 (mg/kg/day) BD (mg/kg/day) S. pneumoniae ATCC 10813 GAR-936 7.3 1.6 1.4 WAY 152,288 7.3 1.9 1.6 ATCC 49619 GAR-936 5.0 1.7 2.0 WAY 152,288 5.0 1.4 1.7 1199 GAR-936 6.6 1.1 0.8 WAY 152,288 6.6 1.0 0.7 1020 GAR-936 5.3 2.3 2.6 WAY 152,288 5.3 2.2 2.4 1293 GAR-936 6.8 3.5 3.0 WAY 152,288 6.8 2.9 2.5 1396 GAR-936 6.2 9.6 5.9 WAY 152,288 6.2 3.1 2.8 S. aureus ATCC 25923 GAR-936 3.1 4.0 7.2 WAY 152,288 3.5 4.0 4.3 ATCC 33591 GAR-936 4.9 33 23 WAY 152,288 5.6 39 23 ATCC 29213 GAR-936 3.9 25 19 WAY 152,288 4.4 22 12 WIS-2 GAR-936 3.6 41 23 WAY 152,288 3.2 26 16 E. coli ATCC 25922 GAR-936 5.5 11 11 WAY 152,288 5.5 11 6.2 894 GAR-936 5.3 5.8 7.5 WAY 152,288 5.3 12 14 K. pneumoniae ATCC 43816 GAR-936 4.4 115 151 WAY 152,288 4.4 48 82 Open in a separate window a E max is expressed as the log 10 difference in numbers between control animals and treated animals.

    Techniques: In Vivo, Infection, Concentration Assay

    Relationship between pharmacokinetic-pharmacodynamic parameters and therapeutic efficacy of GAR-936 (free drug) against S. pneumoniae 1199 in the neutropenic mouse thigh muscle infection model (R2 = 0.82, 0.83, and 0.54 for panels a, b, and c, respectively). (a) time above the 0.5 × MIC versus effect. (b) Log AUC versus effect. (c) Log Cmax versus effect.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Relationship between pharmacokinetic-pharmacodynamic parameters and therapeutic efficacy of GAR-936 (free drug) against S. pneumoniae 1199 in the neutropenic mouse thigh muscle infection model (R2 = 0.82, 0.83, and 0.54 for panels a, b, and c, respectively). (a) time above the 0.5 × MIC versus effect. (b) Log AUC versus effect. (c) Log Cmax versus effect.

    Article Snippet: The sigmoid curve represents the dose-effect curve established according to the Hill equation. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Drug E max a ED 50 (mg/kg/day) BD (mg/kg/day) S. pneumoniae ATCC 10813 GAR-936 7.3 1.6 1.4 WAY 152,288 7.3 1.9 1.6 ATCC 49619 GAR-936 5.0 1.7 2.0 WAY 152,288 5.0 1.4 1.7 1199 GAR-936 6.6 1.1 0.8 WAY 152,288 6.6 1.0 0.7 1020 GAR-936 5.3 2.3 2.6 WAY 152,288 5.3 2.2 2.4 1293 GAR-936 6.8 3.5 3.0 WAY 152,288 6.8 2.9 2.5 1396 GAR-936 6.2 9.6 5.9 WAY 152,288 6.2 3.1 2.8 S. aureus ATCC 25923 GAR-936 3.1 4.0 7.2 WAY 152,288 3.5 4.0 4.3 ATCC 33591 GAR-936 4.9 33 23 WAY 152,288 5.6 39 23 ATCC 29213 GAR-936 3.9 25 19 WAY 152,288 4.4 22 12 WIS-2 GAR-936 3.6 41 23 WAY 152,288 3.2 26 16 E. coli ATCC 25922 GAR-936 5.5 11 11 WAY 152,288 5.5 11 6.2 894 GAR-936 5.3 5.8 7.5 WAY 152,288 5.3 12 14 K. pneumoniae ATCC 43816 GAR-936 4.4 115 151 WAY 152,288 4.4 48 82 Open in a separate window a E max is expressed as the log 10 difference in numbers between control animals and treated animals.

    Techniques: Infection

    Nonlinear regression analysis of the results of the experimental thigh muscle infection on predictors of drug efficacy a

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Nonlinear regression analysis of the results of the experimental thigh muscle infection on predictors of drug efficacy a

    Article Snippet: The sigmoid curve represents the dose-effect curve established according to the Hill equation. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Drug E max a ED 50 (mg/kg/day) BD (mg/kg/day) S. pneumoniae ATCC 10813 GAR-936 7.3 1.6 1.4 WAY 152,288 7.3 1.9 1.6 ATCC 49619 GAR-936 5.0 1.7 2.0 WAY 152,288 5.0 1.4 1.7 1199 GAR-936 6.6 1.1 0.8 WAY 152,288 6.6 1.0 0.7 1020 GAR-936 5.3 2.3 2.6 WAY 152,288 5.3 2.2 2.4 1293 GAR-936 6.8 3.5 3.0 WAY 152,288 6.8 2.9 2.5 1396 GAR-936 6.2 9.6 5.9 WAY 152,288 6.2 3.1 2.8 S. aureus ATCC 25923 GAR-936 3.1 4.0 7.2 WAY 152,288 3.5 4.0 4.3 ATCC 33591 GAR-936 4.9 33 23 WAY 152,288 5.6 39 23 ATCC 29213 GAR-936 3.9 25 19 WAY 152,288 4.4 22 12 WIS-2 GAR-936 3.6 41 23 WAY 152,288 3.2 26 16 E. coli ATCC 25922 GAR-936 5.5 11 11 WAY 152,288 5.5 11 6.2 894 GAR-936 5.3 5.8 7.5 WAY 152,288 5.3 12 14 K. pneumoniae ATCC 43816 GAR-936 4.4 115 151 WAY 152,288 4.4 48 82 Open in a separate window a E max is expressed as the log 10 difference in numbers between control animals and treated animals.

    Techniques: Infection

    Relation between effect of GAR-936 on number of CFU in the thigh after 24 h of therapy in a thigh muscle infection caused by S. pneumoniae ATCC 10813 in neutropenic mice and percent survival after 5 days (2) of treatment. The sigmoid curve represents the dose-effect curve according to the Hill equation. ●, mice for which the effect on the number of CFU was established; each point in the curve represents an individual mouse; ○, mice for which the survival percentage was established (five mice per group).

    Journal:

    Article Title: In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

    doi:

    Figure Lengend Snippet: Relation between effect of GAR-936 on number of CFU in the thigh after 24 h of therapy in a thigh muscle infection caused by S. pneumoniae ATCC 10813 in neutropenic mice and percent survival after 5 days (2) of treatment. The sigmoid curve represents the dose-effect curve according to the Hill equation. ●, mice for which the effect on the number of CFU was established; each point in the curve represents an individual mouse; ○, mice for which the survival percentage was established (five mice per group).

    Article Snippet: The sigmoid curve represents the dose-effect curve established according to the Hill equation. table ft1 table-wrap mode="anchored" t5 TABLE 3 caption a7 Strain Drug E max a ED 50 (mg/kg/day) BD (mg/kg/day) S. pneumoniae ATCC 10813 GAR-936 7.3 1.6 1.4 WAY 152,288 7.3 1.9 1.6 ATCC 49619 GAR-936 5.0 1.7 2.0 WAY 152,288 5.0 1.4 1.7 1199 GAR-936 6.6 1.1 0.8 WAY 152,288 6.6 1.0 0.7 1020 GAR-936 5.3 2.3 2.6 WAY 152,288 5.3 2.2 2.4 1293 GAR-936 6.8 3.5 3.0 WAY 152,288 6.8 2.9 2.5 1396 GAR-936 6.2 9.6 5.9 WAY 152,288 6.2 3.1 2.8 S. aureus ATCC 25923 GAR-936 3.1 4.0 7.2 WAY 152,288 3.5 4.0 4.3 ATCC 33591 GAR-936 4.9 33 23 WAY 152,288 5.6 39 23 ATCC 29213 GAR-936 3.9 25 19 WAY 152,288 4.4 22 12 WIS-2 GAR-936 3.6 41 23 WAY 152,288 3.2 26 16 E. coli ATCC 25922 GAR-936 5.5 11 11 WAY 152,288 5.5 11 6.2 894 GAR-936 5.3 5.8 7.5 WAY 152,288 5.3 12 14 K. pneumoniae ATCC 43816 GAR-936 4.4 115 151 WAY 152,288 4.4 48 82 Open in a separate window a E max is expressed as the log 10 difference in numbers between control animals and treated animals.

    Techniques: Infection